Looking good is feeling good. It may sound cliché, but the reality is that there's a meaningful correlation between health and beauty, and consumers who are proactive about their health also take a greater interest in their personal appearance.
It was only a matter of time before a Hispanic-centric OTC product with roots in South America started making its way toward the top of consumer packaged goods sales lists. Bristol-Myers Squibb de Mexico's Sal de Uvas Picot is the third-largest liquid/powder antacid brand on the market today for the 12 weeks ended April 21.
Products that claim to hydrate spark some high levels of interest for consumers, so it comes as little surprise that sales of facial moisturizers are on the rise. According to data provided by IRI, sales of facial moisturizers rose nearly 3% to more than $404 million during the 52 weeks ended April 21 at total U.S. multi-outlets.
Molson Coors Brewing Company is showcasing a global lineup of product innovations designed to expand its portfolio and provide consumers with variety as the summer season kicks off. The company has planned new releases in Canada, Europe and the United States.
Denver-based organic soda company Oogave has begun distribution of its new all-natural diet soda line, Loca, through Fresh Market stores and Whole Foods Northern California. The company also continues to expand the distribution of its original Oogave soda line through Super Target stores nationwide.
The Food and Drug Administration last month announced that it has approved an amended application submitted by Teva Women's Health to market Plan B One-Step (levonorgestrel) for use without a prescription by women 15 years of age and older. That approval moved Plan B One-Step from behind the pharmacy counter into the family planning section of the pharmacy.
Fortunately, daily hygiene is more or less recession-proof. Thanks to the near universal usage of soap, bath and shower products, this market has been largely unscathed by the weakened economy and is expected to enjoy growth going forward. That being said, consumers have altered their buying habits of such products in recent years, and are looking for value.
When it announced its fourth-quarter and fiscal year 2013 earnings in April, Rite Aid noted that it performed 2.4 million flu vaccinations, as well as 400,000 vaccinations for pneumonia, shingles and whooping cough. Walgreens administered more than 6.5 million immunizations in 2012, and CVS' totals reached more than 3.5 million.
Understanding the needs of the multicultural marketplace, personal care company Sundial Brands, the maker of SheaMoisture, is working to take a new general market positioning at retail. Richelieu Dennis, founder and CEO of Sundial Brands, talked with Drug Store News about the brand's heritage and how it is catering to the needs of its customers.
The Food Marketing Institute Health and Wellness @Retail held in conjunction with the Global Market Development Center HBW Conference kicked off this week with a mission of bringing together retail pharmacy, nutrition, marketing and merchandising professionals with manufacturers and service providers to share insights on how stores can provide a one-stop shopping experience for today’s shoppers.
Oh, how the eyes still have it — eyelashes to be precise. Sales of false lashes continue to enjoy double-digit growth, as evidenced by the most recent data provided by IRI. Sales of false eyelashes and adhesives rose 11.4% to about $84.8 million for the 52 weeks ended April 21 at total U.S. multi-outlets.
The year is only halfway done, but 2013 is already proving to be a year of particular importance for generic drugs as the industry awaits two important decisions from the Supreme Court and continues to wait for federal biosimilar regulations while fending off efforts to limit the scope of their use at the state level.
While the passage of the Patient Protection and Affordable Care Act of 2010 was a milestone in a number of respects, it also was one of the biggest moments in the history of the generic drug industry since the 1984 passage of the Hatch-Waxman Act, which created an abbreviated regulatory approval pathway for generic pharmaceutical drugs.